Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients

Mikio Sakakibara, Mitsuhiko Kido, Jun Kuribayashi, Hiroshi Okada, Ataru Igarashi, Hiroyuki Kamei, Toshitaka Nabeshima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand-name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes. We chose the brand-name drug Aricept and its GE form donepezil to investigate, from a long-term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQol-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens. Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved. The QOL was maintained upon switching to the GE drug form.

Original languageEnglish
Pages (from-to)174-179
Number of pages6
JournalClinical Psychopharmacology and Neuroscience
Volume13
Issue number2
DOIs
Publication statusPublished - 01-08-2015

Fingerprint

Generic Drugs
Names
Alzheimer Disease
Quality of Life
Pharmaceutical Preparations
donepezil
Pharmacies

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Pharmacology (medical)

Cite this

Sakakibara, Mikio ; Kido, Mitsuhiko ; Kuribayashi, Jun ; Okada, Hiroshi ; Igarashi, Ataru ; Kamei, Hiroyuki ; Nabeshima, Toshitaka. / Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients. In: Clinical Psychopharmacology and Neuroscience. 2015 ; Vol. 13, No. 2. pp. 174-179.
@article{4ca66635322f417c9cfdea73c6025612,
title = "Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients",
abstract = "Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand-name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes. We chose the brand-name drug Aricept and its GE form donepezil to investigate, from a long-term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQol-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens. Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved. The QOL was maintained upon switching to the GE drug form.",
author = "Mikio Sakakibara and Mitsuhiko Kido and Jun Kuribayashi and Hiroshi Okada and Ataru Igarashi and Hiroyuki Kamei and Toshitaka Nabeshima",
year = "2015",
month = "8",
day = "1",
doi = "10.9758/cpn.2015.13.2.174",
language = "English",
volume = "13",
pages = "174--179",
journal = "Clinical Psychopharmacology and Neuroscience",
issn = "1738-1088",
publisher = "Korean College of Neuropsychopharmacology",
number = "2",

}

Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients. / Sakakibara, Mikio; Kido, Mitsuhiko; Kuribayashi, Jun; Okada, Hiroshi; Igarashi, Ataru; Kamei, Hiroyuki; Nabeshima, Toshitaka.

In: Clinical Psychopharmacology and Neuroscience, Vol. 13, No. 2, 01.08.2015, p. 174-179.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients

AU - Sakakibara, Mikio

AU - Kido, Mitsuhiko

AU - Kuribayashi, Jun

AU - Okada, Hiroshi

AU - Igarashi, Ataru

AU - Kamei, Hiroyuki

AU - Nabeshima, Toshitaka

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand-name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes. We chose the brand-name drug Aricept and its GE form donepezil to investigate, from a long-term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQol-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens. Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved. The QOL was maintained upon switching to the GE drug form.

AB - Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand-name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes. We chose the brand-name drug Aricept and its GE form donepezil to investigate, from a long-term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQol-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens. Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved. The QOL was maintained upon switching to the GE drug form.

UR - http://www.scopus.com/inward/record.url?scp=84939544385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939544385&partnerID=8YFLogxK

U2 - 10.9758/cpn.2015.13.2.174

DO - 10.9758/cpn.2015.13.2.174

M3 - Article

VL - 13

SP - 174

EP - 179

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

SN - 1738-1088

IS - 2

ER -